Evidence map›Paper›PMID 42667425›Full record

ArticleActa neuropathologica2026

High levels of cell-free hemoglobin and iron in cerebral thrombi of pre-Omicron COVID-19 stroke patients: novel drivers of SARS-CoV-2-induced prothrombotic state.

María Payá, Cristian Alcahut-Rodríguez, Rosa A Barbella-Aponte, Francisco Hernández-Fernández, Juan D Molina-Nuevo, Gemma Barroso-García, Beatriz Castro-Robles, Susana López-López, Lourdes Arias-Salazar, Óscar Ayo-Martín and 11 more

Abstract read
In one paragraph

Article in Acta neuropathologica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

María PayáResearch Unit, General University Hospital of Albacete, Laurel, s/n, 02008, Albacete, Spain.
Cristian Alcahut-RodríguezDepartment of Neurology, General University Hospital of Albacete, Hermanos Falcó, 37, 02008, Albacete, Spain.
Rosa A Barbella-AponteDepartment of Surgical Pathology, General University Hospital of Albacete, Albacete, Spain.
Francisco Hernández-FernándezDepartment of Neurology, General University Hospital of Albacete, Hermanos Falcó, 37, 02008, Albacete, Spain.
Juan D Molina-NuevoResearch Group on Cerebrovascular, Neurodegenerative, and Neuro-Oncological Diseases, Health Research Institute of Castilla-La Mancha (IDISCAM), Albacete, Spain.
Gemma Barroso-GarcíaSESCAM, SAI-Proteómica, Hospital Nacional de Parapléjicos, SAI-HNP-IDISCAM, Toledo, Spain.
Beatriz Castro-RoblesResearch Unit, General University Hospital of Albacete, Laurel, s/n, 02008, Albacete, Spain.
Susana López-LópezResearch Unit, General University Hospital of Albacete, Laurel, s/n, 02008, Albacete, Spain.
Lourdes Arias-SalazarResearch Unit, General University Hospital of Albacete, Laurel, s/n, 02008, Albacete, Spain.
Óscar Ayo-MartínDepartment of Neurology, General University Hospital of Albacete, Hermanos Falcó, 37, 02008, Albacete, Spain.
Jorge García-GarcíaDepartment of Neurology, General University Hospital of Albacete, Hermanos Falcó, 37, 02008, Albacete, Spain.
Blanca Yélamos-SanzResearch Unit, General University Hospital of Albacete, Laurel, s/n, 02008, Albacete, Spain.
Natalia García-FloresResearch Unit, General University Hospital of Albacete, Laurel, s/n, 02008, Albacete, Spain.
Alba G ArandillaSESCAM, SAI-Proteómica, Hospital Nacional de Parapléjicos, SAI-HNP-IDISCAM, Toledo, Spain.
Rafael Moreno-LunaPathophysiology and Regenerative Medicine Group, Hospital Nacional de Parapléjicos, Servicio de Salud de Castilla-La Mancha (SESCAM), 45071, Toledo, Spain.
Alicia Aliena-ValeroUnidad Mixta de Investigación Cerebrovascular, Área de Neurociencias y Salud Mental, Instituto de Investigación Sanitaria La Fe, Valencia, Spain.
Isabel Vielba-GómezUnidad Mixta de Investigación Cerebrovascular, Área de Neurociencias y Salud Mental, Instituto de Investigación Sanitaria La Fe, Valencia, Spain.
José I TemblUnidad Mixta de Investigación Cerebrovascular, Área de Neurociencias y Salud Mental, Instituto de Investigación Sanitaria La Fe, Valencia, Spain.
Juan B SalomUnidad Mixta de Investigación Cerebrovascular, Área de Neurociencias y Salud Mental, Instituto de Investigación Sanitaria La Fe, Valencia, Spain.
Gemma Serrano-Heras *Research Unit, General University Hospital of Albacete, Laurel, s/n, 02008, Albacete, Spain. gemmas@sescam.jccm.es.ORCID https://orcid.org/0000-0001-9368-4832
Tomás Segura *Department of Neurology, General University Hospital of Albacete, Hermanos Falcó, 37, 02008, Albacete, Spain. tseguram@gmail.com.

Funding

Fundación Hospital Nacional de Parapléjicos-IDISCAM Refuerzo de la actividad investigadora de Castilla‑La Mancha (EMER)Instituto de Salud Carlos III RICORS-Ictus (RD21/0006/0002 and RD24/0009/0008)
6 · The paper itself

Abstract

The pathophysiological mechanisms underlying the hypercoagulable state and thrombotic events associated with COVID-19 remain incompletely understood. To investigate prothrombotic alterations during SARS-CoV-2 infection, we performed an exploratory and integrated analysis of cerebral thrombi retrieved, during the first wave of the pandemic, by mechanical thrombectomy from stroke patients with (n=6) and without (n=6) COVID-19. We combined histological and ultrastructural assessment with quantitative proteomics and elemental profiling to identify differences in cellular organization and in protein and metal composition. Immunohistochemical quantification revealed a trend toward increased macrophage abundance, a more diffuse CD68⁺ staining pattern, and reduced platelet content in COVID-19 thrombi. In contrast, neutrophil extracellular traps (NETs) burden, neutrophil number, and erythrocyte content did not differ significantly between groups. Transmission electron microscopy showed a disorganized ultrastructural fibrillar network in thrombi from COVID-19 stroke patients, consistent with the irregular and less densely packed extracellular matrix observed by Masson's trichrome staining. Furthermore, quantitative proteomics by liquid chromatography-tandem mass spectrometry (LC-MS/MS) identified 48 differentially expressed proteins among 720 shared proteins, with marked upregulation of hemoglobin subunits (α, β, γ, and δ), haptoglobin, biliverdin reductase and redox-regulating proteins, alongside downregulation of platelet-related proteins in COVID-19 thrombi. Total reflection X-ray fluorescence (TXRF) confirmed increased iron levels in COVID-19-associated thrombi. Notably, glycophorin A immunostaining did not indicate increased erythrocyte abundance, and erythrocyte structural proteins were not differentially expressed in proteomic analysis, suggesting that hemoglobin and iron were largely present in a cell-free form within the retrieved thrombi of COVID-19 stroke patients. In addition, acute-phase reactants, classical complement components, and immunoglobulins were detected exclusively in COVID-19 samples, consistent with a distinctive immune-inflammatory and oxidative signature. Overall, these findings support a novel pathophysiological mechanism underlying COVID-19-associated hypercoagulability and thrombosis, involving elevated circulating cell-free hemoglobin and increased iron content. Furthermore, this study highlights the potential contribution of hemoglobin/iron-related processes to the COVID-19 prothrombotic state and may provide molecular targets for future therapeutic strategies.

Indexed as

COVID-19HemoglobinsIntracranial ThrombosisIronStrokeAgedAged, 80 and overFemaleHumansMaleMiddle AgedPandemicsProteomicsSARS-CoV-2HemoglobinsIronCOVID-19HemoglobinHypercoagulabilityIronProthrombotic stateQuantitative proteomicsStroke

Identifiers

PMID42667425
PMCPMC13525952

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.